New Zealand markets open in 1 hour 42 minutes

G1 Therapeutics, Inc. (GTHX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
12.81-0.05 (-0.39%)
At close: 04:00PM EDT
12.82 +0.01 (+0.08%)
After hours: 04:09PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close12.86
Open12.84
Bid12.00 x 1100
Ask13.00 x 2200
Day's range12.02 - 12.90
52-week range3.84 - 16.65
Volume658,346
Avg. volume1,271,962
Market cap547.586M
Beta (5Y monthly)2.20
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    G1 Therapeutics Provides Second Quarter 2022 Financial Results and Operational Highlights

    - Achieved $8.7 Million in Net Revenue from Sales of COSELA® (trilaciclib) in the Second Quarter of 2022 and $10.6 Million in Total Revenue - - Completed Patient Enrollment in Pivotal Phase 3 Trial of Trilaciclib in Metastatic Colorectal Cancer (mCRC) (PRESERVE 1) - - Completed Patient Enrollment in Phase 2 Mechanism of Action Trial of Trilaciclib in Neoadjuvant Triple Negative Breast Cancer (TNBC) - - Achieved Target Enrollment in Phase 2 Trial of Trilaciclib in Bladder Cancer (mUC) (PRESERVE 3

  • GlobeNewswire

    G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 10,800 shares of G1’s common stock and 7,200 restricted stock units (RSUs) to two hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Amended and Restated 2021 Plan”). These equity awards were granted as an inducement material to

  • GlobeNewswire

    G1 Therapeutics to Participate Virtually in the 2022 BTIG Biotechnology Conference and the 2022 Wedbush Pacgrow Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upcoming virtual investor conferences in August 2022. On Tuesday August 9, 2022, G1’s Chief Executive Officer Jack Bailey and other members of the executive team will participate in the virtual 2022 BTIG Biotechnology Conference. BTIG-hosted events are intended for prospective and existing BTIG clients